The FDA recently granted 510k clearance to market MagVita TMS therapy, a repetitive transcranial magnetic stimulation system, for treatment of depression.

“The new FDA cleared MagVita TMS Therapy system is tailor-made for health care professionals seeking an entry-level TMS system without having to compromise on quality and safety,” Kerry Rome, BS, vice president of sales at MagVenture Inc, said in a press release.

The MagVita TMS therapy system was first cleared by the FDA in 2015 for treatment of major depressive disorder.

[Read the Full Press Release Here]